Target intelligence / Profile preview

Aureolysin

Molecular classification: Metalloproteinase, Metallopeptidase, Enzyme

Overview

Aureolysin is an extracellular zinc-dependent metalloproteinase produced by Staphylococcus aureus. It is a major virulence factor contributing to immune evasion and infection persistence by inhibiting complement-mediated phagocytosis, degrading antimicrobial peptides and complement proteins, and inactivating serpin-type serine peptidase inhibitors. Its role in infection dynamics includes facilitating the transition from biofilm-forming to invasive phenotypes. Due to its central role in immune evasion, it is a promising drug target for anti-infective development.

Mechanism of action

Inhibition of metalloproteinase activity of Aureolysin

Biological functions

VirulenceImmune evasionProteolysis

Disease associations

InfectionOsteomyelitis

Safety considerations

Potential for off-target effects on other metalloproteinasesDevelopment of resistance

Beyond the preview

Go deeper on Aureolysin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aureolysin.

Explore the full profile